EVALUATION OF THE TOLERABILITY AND BIOMEDICAL POTENTIAL OF A GARMENT CONTAINING PRINTED CERAMICS IN MUSCULAR PAIN

NCT07274293 | Completed

• 2 other identifiers: 1115/CEUniversity of Eastern Piedmont
• Study Type: interventional
• Target: 50
• Locations: 1 country
• Sites: 1

Brief Summary

Today, a new revolution is underway in the textile industry with the introduction of new technologies that add special functions and properties to fabrics. This innovative revolution will see clothing used not only to protect the body from atmospheric changes or for aesthetic purposes, but also to positively influence health. In this sense, nanoparticles play a key and significant role in this technological evolution as they exhibit exceptional surface properties that allow their effect to be multiplied in comparison to bulky additives and traditional materials. With the development of better technology to deliver pure far infrared radiation (FIR), the benefits of its effects have expanded. The main source of energy needed to power FIR emission from clothing comes from the human body, as it has a higher temperature than the surrounding air. Therefore, energy from the human body is transferred to these ceramic particles, which act as "perfect absorbers," maintaining their temperature at a sufficiently high level and emitting FIR back to the body. At the application level, these fabrics have a wide range of uses, depending on the target of FIR therapy, allowing even in specific conditions to level the concentration of lactic acid, a biological marker associated with cardiovascular diseases and toxins. Other potential benefits include an increase in blood oxygen concentration, improved oxygen and nutrient transport to soft tissues, and muscle relaxation. This potentially prevents contractures while improving muscle tone and alleviating muscle soreness and spasms. This type of tissue approach is a more efficient and less invasive way to provide relief in the area affected by pain, so that it can quickly alleviate muscle pain, cramps, and fatigue, and reduce inflammation.

Conditions

Cervical Pain; Lumbar Pain; Muscular; Chronic Pain (Back / Neck); Pain Management

Outcome Measures

Primary Outcomes (1)

• Measuring quality of life

  Measuring quality of life, described with the EURO-QoL-5D-5L or EQ-5D-5L. The instrument consists of: a 5-dimensional descriptive system (mobility, self-care ability, habitual activities, pain/discomfort, and anxiety/depression), each of which involves a three-point rating scale (no problem=1 point; some problem=2 points; persistent problem=3 points); and a VAS that requires the subject to answer the question, "How healthy do you feel today?" A score of 0 corresponds to the worst health status ever, while 100 equals the best perceived health level. It is possible to combine the scores of the two sections and determine an overall score.

  - T0: baseline - T1: after 7 days - T2: after 30 days

Secondary Outcomes (4)

• Measuring the patient's state of well-being

  - T0: baseline - T1: after 7 days - T2: after 30 days

• Perceived comfort when wearing DZero

  - T0: baseline - T1: after 7 days - T2: after 30 days

• Measurement of pain perception and its sensory dimensions

  -T0: baseline - T1: after 7 days; - T2: after 30 days

• Assess your perception of fatigue during normal daily activities

  -T0: baseline -T1: after 7 days -T2: after 30 days

Study Arms (1)

DZero

EXPERIMENTAL

The DZero product is a new smart fabric containing nanoceramic particles printed on non-compressive elastic fabric, with valuable biomedical and biophysical properties designed to improve human health. It is a non-commercialized, non-invasive medical device that does not release substances onto or into the human body, but achieves its intended use by exploiting body energy. DZero, associated with the manufacturer Noivita s.r.l.s. falls within the category of Class I Medical Devices and is also included in the section ("Miscellaneous Equipment for Physiotherapy and Rehabilitation") in the official database of the Italian Ministry of Health. As a Class I medical device, the manufacturer does not need to involve a notified body for CE marking in the process of demonstrating compliance with the requirements of the MDR, but is itself responsible for issuing the EC declaration of conformity in accordance with Article 19 of the MDR 2017/745, after carrying out the appropriate checks.

Device: DZero

Interventions

DZero DEVICE

Each person who agreed to participate was given a DZero garment in the form of a T-shirt suitable for their size, so that the garment would fit snugly to the patient's body. The delivery was made by the principal investigator or a specially designated collaborator, who were directly supplied with T-shirts by the Promoter in collaboration with the study manufacturer, who is the direct supplier. The T-shirt was worn for 8 consecutive hours to best express the intrinsic properties related to its components, namely reducing inflammatory conditions and improving muscle tone using body heat. The innovation lies in the engineering of a new smart fabric that, for the first time, integrates nanoceramics and postural structure, exploiting the characteristics of both materials (bioceramics and fabric) to provide significant benefits for improving health and quality of life on a daily basis.

DZero

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Aged between 18 and 55;
• Presence of neck or lower back pain for at least 3 months;
• Use of paracetamol in the last 3 months;
• Self-sufficient patients, able to carry out normal daily activities even after wearing the shirt;
• Patients who agree to sign the informed consent form.

You may not qualify if:

• Pregnant or breastfeeding patients;
• Presence of chronic malignant diseases;
• Presence of mild/moderate spasticity;
• Use of pharmacological treatments for neuropathic pain (e.g., nicetile, tricyclic antidepressants, opioids, antiepileptics);
• Presence of known severe concomitant brain damage;
• Presence of known concomitant severe brain damage;
• Presence of psychiatric or neurological disorders;
• Presence of tumors or terminal illnesses;
• Alcohol or substance abuse;
• Hypersensitivity to the product;
• Lack of knowledge of the Italian language;
• Participation in other clinical trials in the last 3 months.

Sponsors & Collaborators

• noiVita Srls: lead
• University of Eastern Piedmont: collaborator

Study Sites (1)

DAIRI, Alessandria, 15121

Alessandria, Italy

Location

MeSH Terms

Conditions

Neck Pain; Low Back Pain; Chronic Pain; Agnosia

Condition Hierarchy (Ancestors)

Pain; Neurologic Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms; Back Pain; Perceptual Disorders; Neurobehavioral Manifestations; Nervous System Diseases

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 27, 2025
• First Posted: December 10, 2025
• Study Start: May 6, 2025
• Primary Completion: June 12, 2025
• Study Completion: October 13, 2025
• Last Updated: December 10, 2025

Record last verified: 2025-10

Data Sharing

• IPD Sharing: Will not share

Locations

IT (1)